Type of Financing January February Total ($M) Public offerings 2,305.0 269.1 2,574.1 Public/other 530.4 238.9 769.3 Private biotechs 210.2 161.9 372.0 Total ($M) 3,045.6 669.9 3,715.4 Notes: Public offerings = Initial, follow-on. Private biotechs = Financings of private firms. Public/other = Other financings of public companies, including loans, bridge financings, exercises of warrants, debt offerings, rights offerings, standard private placements, PIPE financings and institutional offerings

TOTAL: $238.9M Company (Location) Type Of Financing Number Of Shares, Units Or Warrants (M) Amount| Raised (M) Investors; Placement Agents; Details Date Amarantus BioScience Inc. (Sunnyvale, Calif.) Convertible note financing N/A $1.4 Amarantus secured an additional $1.4M in financing commitments through an amendment of its initial $600,000 convertible note, issued in November 2012 to Dominion Capital, to $2M 2/1/13 BioLineRx Ltd. (Jerusalem) American depositary shares agreement 2.7ADS

Company Amount Raised Ironwood Pharmaceuticals Inc. $175M OPKO Health Inc. $175M Pacira Pharmaceuticals Inc. $110M e-Therapeutics plc $62.66M

Total: $161.9M Company Location Amt. (M) Details Date Aduro BioTech Inc. Berkeley, Calif. $6.5 Aduro raised $6.5M in an equity financing primarily from current investors 2/1/13 Aerial BioPharma Inc. Morrisville, N.C. $12 Aerial raised $12M in a Series A round 2/21/13 Antabio Lebege, France €4.7 ($6.4) Antabio received a $6.4M Wellcome Trust Seeding Drug Discovery Award 2/4/13 Apceth GmbH and Co. Munich, Germany ND Apceth raised an undisclosed amount in a second round of financing 2/6/13 Aviir

Company Amount Raised Jounce Therapeutics Inc. $47M Labrys Biologics Inc. $31M Versartis Inc. $25M Gradalis Inc. $24M Marinus Pharmaceuticals Inc. $21M Elcelyx Therapeutics Inc. $20M Solstice Biologics LLC $18M

Total: $14.1M Year to Date: $56.75M Company (Location) Partner (Location) Amt. (M) Details Date Isis Pharmaceuticals Inc. (Carlsbad, Calif.) GlaxoSmithKline plc (London) $7.5 For the start of a Phase II/III study of ISIS-TTRRx 2/20/13 Medivir AB (Huddinge, Sweden) Janssen Pharmaceuticals Inc. (part of Johnson & Johnson; New Brunswick, N.J.) €5 ($6.6) For the submission of a regulatory application in Japan for simeprevir to treat genotype 1 chronic hepatitis C 2/25/13 Merus BV (Utrecht, the

Somewhere along the way from the heady days of the dot-com era in 2000 the "magic" of achieving a successful biotech initial public offering (IPO) seems to have been lost. Time was that for biotech companies and the venture capitalists who invested in them, a public stock offering was the first major milestone of business and financial success – a preferred exit strategy for VCs and an opportunity for companies to access future public market capital financings and adequately fund their product

As outlined in the first part of this article scanning the rapidly evolving technology landscape of bispecific and multispecific antibodies, interest in them has been renewed big time because various manufacturing, stability and safety issues have been addressed. The field now encompasses a multitude of approaches for creating antibodies against a variety of targets and the number of companies entering this space is surging. (See BioWorld Insight, Feb. 19, 2013.) Although some companies have

After seeing its clinical program stall following the failure of a Phase IIb trial testing NTx-265 in acute stroke, Stem Cell Therapeutics Corp. is reinventing itself. (See BioWorld Today, May 26, 2010.) The first step was hiring David Allan as the executive chairman of the Toronto, Canada-based company. Allan was the founding CEO and chairman of YM BioSciences Inc., which was recently sold to Gilead Sciences Inc. for $510 million (See BioWorld Today, Dec. 13, 2012.) "The Stem Cell board called

The field of hepatitis C virus (HCV) research is hot. So hot, in fact, that in January the BioWorld Today staff ranked the unfolding story of the exceptional performance of HCV potential treatments from the clinic in second place in the top 10 most impactful stories of last year. (See BioWorld Today, Jan. 2, 2013.) Not surprising really as the momentum from 2011 kicked into high gear in 2012. In April, Gilead Sciences Inc. of Foster City, Calif., reported a 100 percent sustained virologic

Financings Aerial BioPharma Inc. completed the second tranche of its $12 million Series A financing. Ambit Biosciences Inc. filed for an initial public offering seeking to raise up to $57.5 million. Novelos Therapeutics Inc. closed a public offering of 11 million units at $0.50 per unit. Oncolytics Biotech Inc. priced a public stock sale of 8 million shares at $4 each. PolyActiva Pte. Ltd. raised $9.5 million in a Series B financing from a consortium of investors. Sernova Corp. raised $1.9

"Outside the U.S. there does not exist a capital market for the life sciences." – David Allan, executive chairman of Stem Cell Therapeutics Corp. "The best outcome may be a reverse merger by a private company seeking to utilize Phytopharm's cash, London Stock Exchange listing and accumulated tax losses." – Robin Davison, analyst, Edison Investment Research on Phytopharm's failure of it lead program in Parkinson's disease "Most companies that have delivery technology . . . They do a little

The Patent and Trademark Office (PTO) expects an increased number of filings over the next few weeks as firms rush to file new patents before the reforms of the America Invents Act (AIA) take effect March 16. The PTO has rolled out a slew of new regulations and guidances to implement the switch from first-to-invent to first-to-file, as well as other changes in this sweeping reform. The U.S. Court of Appeals for the Federal Circuit agreed with a federal district court that Teva Pharmaceutical